Zymeworks (NYSE:ZYME - Free Report) had its price target upped by HC Wainwright from $12.00 to $13.00 in a research note released on Monday,Benzinga reports. The firm currently has a neutral rating on the stock. HC Wainwright also issued estimates for Zymeworks' Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.95) EPS.
ZYME has been the subject of several other research reports. Citigroup raised their target price on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. JPMorgan Chase & Co. upgraded Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price for the company in a research note on Monday, December 16th. Finally, Wells Fargo & Company raised their price target on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Zymeworks currently has an average rating of "Moderate Buy" and an average price target of $21.00.
Check Out Our Latest Analysis on Zymeworks
Zymeworks Trading Up 2.4 %
Shares of ZYME stock traded up $0.31 on Monday, hitting $12.86. 51,600 shares of the stock were exchanged, compared to its average volume of 478,048. The firm has a market capitalization of $894.41 million, a PE ratio of -8.67 and a beta of 1.13. Zymeworks has a one year low of $7.97 and a one year high of $17.70. The firm's 50 day moving average is $13.92 and its two-hundred day moving average is $13.64.
Insiders Place Their Bets
In other news, Director Ecor1 Capital, Llc purchased 11,958 shares of the company's stock in a transaction that occurred on Tuesday, December 24th. The shares were bought at an average cost of $14.12 per share, for a total transaction of $168,846.96. Following the completion of the transaction, the director now directly owns 14,704,239 shares of the company's stock, valued at $207,623,854.68. This trade represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kenneth Galbraith sold 57,291 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $854,781.72. Following the completion of the transaction, the chief executive officer now owns 47,543 shares of the company's stock, valued at $709,341.56. This represents a 54.65 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 1,392,585 shares of company stock valued at $17,914,519 and have sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Zymeworks by 0.8% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company's stock worth $24,416,000 after purchasing an additional 14,604 shares during the last quarter. Deutsche Bank AG grew its position in Zymeworks by 1.2% during the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock valued at $22,645,000 after buying an additional 17,849 shares during the period. State Street Corp grew its position in Zymeworks by 6.1% during the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock valued at $14,706,000 after buying an additional 67,401 shares during the period. Dimensional Fund Advisors LP grew its position in Zymeworks by 14.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock valued at $14,240,000 after buying an additional 123,240 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in Zymeworks by 2.3% during the fourth quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock valued at $11,121,000 after buying an additional 17,092 shares during the period. Institutional investors own 92.89% of the company's stock.
About Zymeworks
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Read More
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
